Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S held its Annual General Meeting on 30 March 2026 at 09:00 CET at Strandvejen 60, 2900 Hellerup. Mikkel Rostock-Jensen was elected Chairman of the meeting, and the chair confirmed no shareholder objections and that the meeting was duly convened and legally competent.

Analysis

An uneventful governance calendar at a small-cap typically removes short-term headline risk but raises the bar for value realization: with continuity in control, any re-rating must come from operational improvement or a discrete corporate action (asset sale, bolt-on M&A, or dividend initiation). Expect a 6–12 month runway for substantive value catalysts to appear; absent those, market pricing will increasingly reflect liquidity and free-float constraints rather than fundamentals, compressing trading multiples by 10–25% versus more liquid peers.

Second-order beneficiaries of a quiet AGM are activist managers and event-driven funds that can accumulate blocks unnoticed and then push for change on a timetable; the cost of entry in illiquid Danish small-caps can be 100–300bps of market cap per 1% ownership, making 2–3% stakes a realistic threshold for influence. Conversely, sell-side research and passive vehicles lose interest, increasing information asymmetry and volatility on any unexpected news — intra-day moves of 15–40% are not uncommon when thinly-traded names face new information.

Key tail risks: a delayed disclosure (restatement, material contract change) or an opportunistic bidder can flip the situation quickly — both can occur inside 30–90 days and produce >50% moves. Catalysts to watch are insider/management share purchases, new debt issuance, or regulatory filings; each has >60% probability of shifting market sentiment within two quarters if coupled with visible cash-flow improvement.

Key Decisions for Investors

• Event-driven small-cap accumulation (12-month horizon): build a 1–2% position in an equal-weighted basket of 8–12 Danish microcaps with sub-€500m market caps (avoid names with >40% insider lockups). Hedge market risk by shorting NOVO-B.CO (Novo Nordisk B) sized to net 0 beta vs European health/large-cap exposure. Target return 25–40% if one activist-catalyst or M&A occurs; downside capped at 20–30% if liquidity dries up.
• Catalyst-triggered option play (3–6 months): upon documented insider buy >0.5% or regulatory clearance filings, buy 6–9 month call spreads on the target small-cap (or on a comparable liquid proxy) to limit capital at risk while retaining upside capture. Allocate no more than 1–2% of NAV to this strategy; expected asymmetric payoff 3:1 skew if catalyst materializes, total loss limited to premium paid.
• Information-asymmetry premium harvest (6–12 months): deploy a convertible arbitrage / long-bias in illiquid names with stable cash flows and governance continuity; finance with secured short positions in ORSTED.CO (Orsted) or VWS.CO (Vestas) to offset sector risk. Aim for 8–12% annualized carry plus 15–30% upside on successful governance-driven events; primary risk is forced deleveraging in stress periods leading to 25–40% mark-to-market drawdowns.
• Monitoring & risk controls (ongoing): set automated alerts for filings, insider trades, and 30-day VWAP shifts >15%; if two triggers occur, scale exposure up to target position over 5 trading days. Stop-loss framework: trim 50% of position on -20% move absent new fundamental news, and cut fully if liquidity widens bid-ask by >200bps or daily volume falls below the 3-month median by 60%.